Stock PAHC PHIBRO ANIMAL HEALTH CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Phibro Animal Health Corporation

Equities

PAHC

US71742Q1067

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
17.63 USD -0.96% Intraday chart for Phibro Animal Health Corporation -4.96% +52.25%
May. 09 Transcript : Phibro Animal Health Corporation, Q3 2024 Earnings Call, May 09, 2024
May. 08 Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q3 EPS $0.31, vs. Street Est of $0.29 MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,285 1,063 1,170 774.8 554.9 714.1 - -
Enterprise Value (EV) 1 1,530 1,358 1,170 1,117 948.5 946.6 1,102 1,093
P/E ratio 23.5 x 31.7 x 21.6 x 15.8 x 16.9 x 53.4 x 24.7 x 20 x
Yield 1.45% 1.83% 1.66% 2.51% 3.5% 2.72% 2.68% 2.67%
Capitalization / Revenue 1.55 x 1.33 x 1.4 x 0.82 x 0.57 x 0.71 x 0.69 x 0.68 x
EV / Revenue 1.85 x 1.7 x 1.4 x 1.18 x 0.97 x 0.94 x 1.07 x 1.04 x
EV / EBITDA 13 x 13.3 x 10.8 x 10.1 x 8.41 x 8.03 x 8.59 x 8.96 x
EV / FCF 17.4 x 20 x 14.9 x - - 17.9 x 29 x 24.8 x
FCF Yield 5.76% 5% 6.72% - - 5.6% 3.45% 4.03%
Price to Book 5.95 x 5.65 x - 2.95 x 1.96 x 2.56 x 2.48 x 2.35 x
Nbr of stocks (in thousands) 40,454 40,454 40,504 40,504 40,504 40,504 - -
Reference price 2 31.77 26.27 28.88 19.13 13.70 17.63 17.63 17.63
Announcement Date 8/27/19 8/26/20 8/25/21 8/24/22 8/30/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 828 800.4 833.4 942.3 977.9 1,003 1,029 1,051
EBITDA 1 118 102.1 107.9 111.1 112.8 117.9 128.3 122
EBIT 1 96.6 78.7 84.7 87.3 88.4 82.42 84.95 97
Operating Margin 11.67% 9.83% 10.16% 9.26% 9.04% 8.22% 8.26% 9.23%
Earnings before Tax (EBT) 1 71.5 55.51 66.5 - 54.1 23 39 51
Net income 1 54.7 33.55 54.4 49.18 32.6 13.39 29.07 35.8
Net margin 6.61% 4.19% 6.53% 5.22% 3.33% 1.34% 2.83% 3.41%
EPS 2 1.350 0.8300 1.340 1.210 0.8100 0.3300 0.7150 0.8800
Free Cash Flow 1 88.11 67.96 78.56 - - 53 38 44
FCF margin 10.64% 8.49% 9.43% - - 5.29% 3.69% 4.19%
FCF Conversion (EBITDA) 74.67% 66.53% 72.81% - - 44.95% 29.61% 36.07%
FCF Conversion (Net income) 161.08% 202.54% 144.42% - - 395.69% 130.72% 122.91%
Dividend per Share 2 0.4600 0.4800 0.4800 0.4800 0.4800 0.4800 0.4733 0.4700
Announcement Date 8/27/19 8/26/20 8/25/21 8/24/22 8/30/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 232.7 239.6 255.3 232.5 244.6 245.7 255 231.3 249.9 263.2 260.5
EBITDA 1 29.1 28 31.53 22.13 30.9 27.4 32.3 18.7 29.5 29.7 40.59
EBIT 1 23.3 21.8 25.5 16.1 24.8 21.3 26.2 12.2 23 23 23.89
Operating Margin 10.01% 9.1% 9.99% 6.92% 10.14% 8.67% 10.27% 5.27% 9.2% 8.74% 9.17%
Earnings before Tax (EBT) - - - - 12.1 15.1 21.4 -12 - - -
Net income 1 17.5 17.69 7.487 3.9 7.2 10 11.5 -8 1.3 8.4 11.73
Net margin 7.52% 7.38% 2.93% 1.68% 2.94% 4.07% 4.51% -3.46% 0.52% 3.19% 4.5%
EPS 2 0.4300 0.4400 0.1800 0.1000 0.1800 0.2500 0.2800 -0.2000 0.0300 0.2100 0.2900
Dividend per Share - - - - - - 0.1200 - - - -
Announcement Date 2/9/22 5/4/22 8/24/22 11/9/22 2/8/23 5/3/23 8/30/23 11/8/23 2/7/24 5/8/24 -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 245 296 - 342 394 233 388 379
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.073 x 2.895 x - 3.076 x 3.489 x 1.972 x 3.023 x 3.107 x
Free Cash Flow 1 88.1 68 78.6 - - 53 38 44
ROE (net income / shareholders' equity) 27.3% 21.7% 25.5% 19.6% 18% 18.3% 15.9% 17.7%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 5.340 4.650 - 6.480 6.980 6.890 7.100 7.500
Cash Flow per Share 2 1.160 1.470 1.930 1.880 - 0.5900 1.250 1.740
Capex 1 29.9 34 29.3 - - 42 40 42
Capex / Sales 3.61% 4.25% 3.52% - - 4.19% 3.89% 4%
Announcement Date 8/27/19 8/26/20 8/25/21 8/24/22 8/30/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Phibro Animal Health Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
17.63 USD
Average target price
13.5 USD
Spread / Average Target
-23.43%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Veterinary Drugs

1st Jan change Capi.
PHIBRO ANIMAL HEALTH CORPORATION Stock Phibro Animal Health Corporation
+52.25% 714M
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
+18.66% 8.74B
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+23.75% 3.67B
VIRBAC Stock Virbac
-0.42% 3.25B
VIMIAN GROUP AB Stock Vimian Group AB
+18.07% 1.73B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-16.99% 1.38B
VETOQUINOL SA Stock Vetoquinol SA
-0.39% 1.31B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-26.05% 1.24B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-17.86% 1.07B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-6.77% 976M
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. PAHC Stock
  4. Financials Phibro Animal Health Corporation